Abstract
In the Prevention of Venous Thromboembolism Following Radical Prostatectomy (PREVENTER) randomized trial, pharmacologic prophylaxis did not reduce the rate of symptomatic (relative risk [RR] 0.40 [95% confidence interval {CI} 0.08–2.03], p = 0.267) or overall (RR 0.97 [95% CI 0.25–3.81], p = 0.967) venous thromboembolism significantly. There was no increase in adverse events including symptomatic lymphoceles or bleeding.
Original language | English |
---|---|
Pages (from-to) | 360-368 |
Number of pages | 9 |
Journal | European Urology |
Volume | 78 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2020 |
Keywords
- Clinical trial
- Evidence-based medicine
- Quality improvement
- Radical prostatectomy
- Surgery
- Venous thromboembolism